Navigation Links
Quetiapine in Medical News

Schizophrenia Drug Got Bad Rap

...ot widen from 1996 (25 years) to 2006 (22.5 years). Compared with current use of perphenazine, the highest risk for death was among patients taking quetiapine (41 percent higher) and the lowest was for clozapine (26 percent lower). The study also found that long-term use (seven to 11 years) of antipsychot...

Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications

...mg/dL) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs.4.6% in patients recei...y significant increases in cholesterol (7%-16% for quetiapine vs. 3%-9% for placebo) and triglycerides (8%-23% for quetiapine vs. 5%-16% for placebo) have been observed in clin...

FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications

...mg/dL) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs. 4.6% in patients rece...y significant increases in cholesterol (7%-16% for quetiapine vs. 3%-9% for placebo) and triglycerides (8%-23% for quetiapine vs. 5%-16% for placebo) have been observed in clin...

Newer Antipsychotics May Boost Weight in Alzheimer's Patients

... Drugs such as olanzapine, quetiapine may also lower 'good' cholesterol, researchers say WEDNESDAY, April 15 (HealthDay News) Newer antipsychotic drugs promote weight gain and...

FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications

...mg/dL) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs. 4.6% in patients rece...y significant increases in cholesterol (7%-16% for quetiapine vs. 3%-9% for placebo) and triglycerides (8%-23% for quetiapine vs. 5%-16% for placebo) have been observed in clin...

FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site

...mg/dL) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs. 4.6% in patients rece...y significant increases in cholesterol (7%-16% for quetiapine vs. 3%-9% for placebo) and triglycerides (8%-23% for quetiapine vs. 5%-16% for placebo) have been observed in clin...

Combating weight gain caused by antipsychotic treatments

... Philadelphia, PA, March 26, 2009 Antipsychotic drugs, such as olanzapine (Zyprexa), risperidone (Risperdal) and quetiapine (Seroquel), are commonly used to treat psychotic disorders like schizophrenia, but also bipolar disorder and even behavioral problems related to demen...

AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression

...mg/dL) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs. 4.6% in patients rece...y significant increases in cholesterol (4%-16% for quetiapine vs. 2%-7% for placebo) and triglycerides (8%-23% for quetiapine vs. 6%-16% for placebo) have been observed in clin...

New Research Study in Houston, Texas Seeks Improved Quality of Life for People in the Future with Schizophrenia

...h schizophrenia at or before age 35 and currently taking one of five medications for schizophrenia which include olanzapine, risperidone/paliperidone, quetiapine or aripiprazole. Participants must also be considered outpatient (living in the community). Qualified study participants will receive all investigat...

Newer Antipsychotics Pose Cardiac Risk: Study

...atients should rarely, if ever, take the drugs to treat other conditions, he said. At issue are newer antipsychotic drugs -- clozapine (Clozaril), quetiapine (Seroquel), olanzapine (Zyprexa) and risperidone (Risperdal). Federal health officials have approved the use of the drugs to treat schizophrenia an...
Quetiapine in Medical Technology

Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study

Separate Study Showed Significantly Improved Functioning Within Three Months WASHINGTON, May 6 /PRNewswire-FirstCall/ -- Nearly half of patients with schizophrenia fail to remain on their medication treatment, which can result in a relapse of symptoms (1,2). To...

AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines

... depression; however, an immediate release form of quetiapine is approved for the treatment of bipolar depressio...mpletely, if antipsychotic treatment is withdrawn. quetiapine should be prescribed in a manner that is most like...mg/dL) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs 4.6% in patients recei...

New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting

...to those reported in previous clinical trials with quetiapine (See detailed study data below).(1-5) MDD affect... depression; however, an immediate release form of quetiapine is approved for the treatment of bipolar depressio...mpletely, if antipsychotic treatment is withdrawn. quetiapine should be prescribed in a manner that is most like...

AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression

...ay remit, partially or completely, if antipsychotic treatment is withdrawn. quetiapine should be prescribed in a manner that is most likely to minimize the occurr...ter than or equal to 126 mg/dL) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs 4.6% in patients receiving placebo (mean exposu...

SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia

...mpletely, if antipsychotic treatment is withdrawn. quetiapine should be prescribed in a manner that is most like...mg/dl) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs 4.6% in patients recei...f schizophrenia relapse with extended release quetiapine fumarate dosed once daily: A randomized, plac...

INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients

... Dirks B, Carothers J et al., A comparative analysis of paliperidone ER and quetiapine in patients with a recent, acute exacerbation of schizophrenia, presented a...s in Orlando, Florida. (2) Citrome L, Jaffe A, Levine J, et al., Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. ...

Seroquel Sustained Release Schizophrenia Data Presented at ECP Congress in Madrid

...rom original formulation quetiapine, there were no significant differences between SEROQUEL sustained release formulation and the original formulation quetiapine in PANSS total scores after six weeks’ treatment (mean PANSS total score at day 42 was 55.4 and 54.8 for the sustained release formulation and t...

New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia

...ntitled: Efficacy of Once-Daily Extended Release quetiapine Fumarate in Patients with Acute Schizophrenia Th...ntitled: Efficacy of Once-Daily Extended Release quetiapine Fumarate across Symptom Domains in Schizophrenia ... "Efficacy of Once-Daily Extended Release quetiapine Fumarate in Patients with Acute Schizophrenia." An...
Quetiapine in Biological News

NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders

...ide dissemination to patients. These have included the anticonvulsants valproate (Depakote) and lamotrigine (Lamictal), and the atypical antipsychotic quetiapine (Seroquel). These agents have vastly enlarged our treatment armamentarium and provided new options for patients with bipolar disorder, making it possi...

Risks and benefits of antipsychotics in children and adolescents

...the naturalistic study conducted by our group in early-onset psychosis patients, weight gain was also greater with olanzapine than with risperidone or quetiapine (Castro-Fornieles et al., in press). Weight gain in children raises the concern that, if treated for long periods, these patients may be at higher ris...
Quetiapine in Biological Technology

Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress

TITUSVILLE, N.J., Oct. 8 /PRNewswire/ -- Preliminary results from a clinical study comparing INVEGA(TM) (paliperidone) Extended-Release Tablets to quetiapine (marketed as Seroquel(R)) and placebo in patients with recent, acute exacerbation of schizophrenia will be the subject of a poster on di...

FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania

...mpletely, if antipsychotic treatment is withdrawn. quetiapine should be prescribed in a manner that is most like...mg/dL) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs. 4.6% in patients rece...fectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar ...

AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder

...tive dose of antipsychotic drugs administered to the patient increase. TD may remit, partially or completely, if antipsychotic treatment is withdrawn. quetiapine should be prescribed in a manner that is most likely to minimize the occurrence of TD. Leukopenia, neutropenia, and agranulocytosis (including fatal...

Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder

...ally relevant, effect on QTc. Asenapine had an effect equal to or less than quetiapine on QTc in this study. The study abstract, "Effect of asenapine versus quetiapine and placebo on QTc interval in patients with schizophrenia," (P.3.c.050) wa...
Other Tags
(Date:4/18/2015)... Lower-auto-insurance.com has released a new blog post ... quotes . , Drivers can find accurate information ... professional insurance brokerage website can help drivers compare the ... convenient way. The whole process is designed to be ... online car insurance quotes is advantageous because it allows ...
(Date:4/18/2015)... York, New York (PRWEB) April 18, 2015 ... ) filed on behalf of individuals who were ... replacement system continue to move forward in the U.S. ... Order dated April 10th, the Court has amended an ... of unrelated cases. Among other things, the new amendment ...
(Date:4/18/2015)... 2015 More than 2000 styles of ... TheCelebrityDresses.com, the #1 online store carrying celebrity inspired special ... have got their perfect dresses for their prom. For ... prom dresses at TheCelebrityDresses.com would be an ideal choice. ... 2000 prom dresses inspired by the most loved styles ...
(Date:4/18/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Association Annual Conference to be held May 1-2, ... , The SCAPTA Annual Conference offers educational ... services. , Representatives from Aureus Medical’s ...
(Date:4/18/2015)... PHOENIX, ARIZONA – In March, Mark Ona, Territory ... destruction professionals across the United States, earned the professional ... display “CSDS” as a professional title with his name. ... of Information Destruction 2015 Annual Conference began - one ... 20 people who took the exam, Ona was amongst ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes Can Provide Accurate Results! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
Other Contents